Overview

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Status:
Completed
Trial end date:
2021-03-12
Target enrollment:
Participant gender:
Summary
This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).
Phase:
Phase 3
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Novaliq GmbH